Literature DB >> 28580534

Fatal Pulmonary Mucormycosis due to Rhizopus homothallicus.

Fabrice Compain1, Nawel Aït-Ammar2,3, Françoise Botterel2,3, Laure Gibault4, Francoise Le Pimpec Barthes5, Eric Dannaoui6,7.   

Abstract

We report here a case of cavitary pneumonia due to Rhizopus homothallicus in a diabetic patient. This is the first proven case of R. homothallicus infection in Western countries and the third case described worldwide. The organism was isolated from lung biopsy and identified after amplification and sequencing of the internal transcribed spacer region.

Entities:  

Keywords:  Case report; Molecular sequence data; Mucorales; Mucormycosis; Rhizopus homothallicus

Mesh：

Substances：

Year:  2017        PMID： 28580534     DOI： 10.1007/s11046-017-0151-7

Source DB:  PubMed          Journal:  Mycopathologia        ISSN： 0301-486X            Impact factor:   2.574


  35 in total

1.  Posaconazole as salvage therapy for zygomycosis.

Authors:  R N Greenberg; K Mullane; J-A H van Burik; I Raad; M J Abzug; G Anstead; R Herbrecht; A Langston; K A Marr; G Schiller; M Schuster; J R Wingard; C E Gonzalez; S G Revankar; G Corcoran; R J Kryscio; R Hare
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

Review 2.  Changing epidemiology of an emerging infection: zygomycosis.

Authors:  J F Meis; A Chakrabarti
Journal:  Clin Microbiol Infect       Date:  2009-10       Impact factor: 8.067

3.  Species boundaries and nomenclature of Rhizopus arrhizus (syn. R. oryzae).

Authors:  Somayeh Dolatabadi; G Sybren de Hoog; Jacques F Meis; Grit Walther
Journal:  Mycoses       Date:  2014-09-30       Impact factor: 4.377

4.  Early clinical and laboratory diagnosis of invasive pulmonary, extrapulmonary, and disseminated mucormycosis (zygomycosis).

Authors:  Thomas J Walsh; Maria N Gamaletsou; Michael R McGinnis; Randall T Hayden; Dimitrios P Kontoyiannis
Journal:  Clin Infect Dis       Date:  2012-02       Impact factor: 9.079

Review 5.  Mucormycosis in India: unique features.

Authors:  Arunaloke Chakrabarti; Rachna Singh
Journal:  Mycoses       Date:  2014-09-03       Impact factor: 4.377

Review 6.  Zygomycetes in human disease.

Authors:  J A Ribes; C L Vanover-Sams; D J Baker
Journal:  Clin Microbiol Rev       Date:  2000-04       Impact factor: 26.132

7.  Spectrum of zygomycete species identified in clinically significant specimens in the United States.

Authors:  E Alvarez; D A Sutton; J Cano; A W Fothergill; A Stchigel; M G Rinaldi; J Guarro
Journal:  J Clin Microbiol       Date:  2009-04-22       Impact factor: 5.948

Review 8.  Lipid formulations of amphotericin B as first-line treatment of zygomycosis.

Authors:  G L Petrikkos
Journal:  Clin Microbiol Infect       Date:  2009-10       Impact factor: 8.067

Review 9.  The ecology of the Zygomycetes and its impact on environmental exposure.

Authors:  M Richardson
Journal:  Clin Microbiol Infect       Date:  2009-10       Impact factor: 8.067

10.  Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group.

Authors:  Ben De Pauw; Thomas J Walsh; J Peter Donnelly; David A Stevens; John E Edwards; Thierry Calandra; Peter G Pappas; Johan Maertens; Olivier Lortholary; Carol A Kauffman; David W Denning; Thomas F Patterson; Georg Maschmeyer; Jacques Bille; William E Dismukes; Raoul Herbrecht; William W Hope; Christopher C Kibbler; Bart Jan Kullberg; Kieren A Marr; Patricia Muñoz; Frank C Odds; John R Perfect; Angela Restrepo; Markus Ruhnke; Brahm H Segal; Jack D Sobel; Tania C Sorrell; Claudio Viscoli; John R Wingard; Theoklis Zaoutis; John E Bennett
Journal:  Clin Infect Dis       Date:  2008-06-15       Impact factor: 9.079
View more
  1 in total

Review 1.  Recent Developments in the Diagnosis of Mucormycosis.

Authors:  Eric Dannaoui
Journal:  J Fungi (Basel)       Date:  2022-04-28
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.